Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6823273 | 0.88 | TYMS (0.32) | CYP2A6 | |
| SCHEMBL6820123 | 0.88 | ERN1 (0.38) | ERN1CYP2A6MEN1MAPTKMT2A | |
| SCHEMBL6819911 | 0.88 | ERN1 (0.38) | ERN1CYP2A6MEN1MAPTKMT2A | |
| SCHEMBL6819304 | 0.87 | ERN1 (0.35) | ERN1CYP2A6MEN1MAPTKMT2A | |
| SCHEMBL6815878 | 0.75 | TDP2 (0.30) | — | |
| SCHEMBL6823596 | 0.75 | CYP2A6 (0.34) | CYP2A6MEN1MAPTKMT2AKDM4E | |
| SCHEMBL6819887 | 0.75 | CYP2A6 (0.34) | CYP2A6MEN1MAPTKMT2AKDM4E | |
| SCHEMBL6823206 | 0.75 | TYMS (0.32) | CYP2A6 | |
| SCHEMBL6822909 | 0.71 | PARP1 (0.33) | — | |
| SCHEMBL6819375 | 0.69 | ERN1 (0.59) | ERN1CYP2A6MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0995734-B1 | Method for production of halogen-containing aromatic compound | NIPPON CATALYTIC CHEM IND (JP) | 2004-05-12 | — | — | EP | disclosed |
| US-6433231-B2 | BROMINATION THE CORRESPONDING NAPHTHALENE HALOGEN COMPOUND | NIPPON SHOKUBAI CO., LTD. (JP) | 2002-08-13 | — | — | US | disclosed |
| US-20010045350-A1 | Method for production of halogen-containing aromatic compound | NIPPON SHOKUBAI CO., LTD., A JAPAN CORPORATION | 2001-11-29 | — | — | US | disclosed |
| US-6288290-B1 | BROMINATION AND PHOTOBROMINATION OF AROMATIC COMPOUNDS | NIPPON SHOKUBAI, CO., LTD. (JP) | 2001-09-11 | — | — | US | disclosed |
| EP-0995734-A1 | Method for production of halogen-containing aromatic compound | Nippon Shokubai Co., Ltd. (JP) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010045350-A1 | Method for production of halogen-containing aromatic compound | CBR1, CBR3, DCXR | ERN1 1246/4885CYP2A6 989/4885MEN1 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.